Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of AZD5718 in Healthy Japanese Men
NCT03400488Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in coronary artery disease (CAD) comparing Atuliflapon with Placebo (2 arms). Primary endpoints: Number of patients with Adverse Events (AEs) due to AZD5817, Supine vital sign (Systolic Blood pressure [BP]) and 8 more. Started Jan 2018; status: completed.
02
Drugs
atuliflapon
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03400488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400488.